Related Experiment Video
Updated: Jan 22, 2026

A Modified Trier Social Stress Test for Vulnerable Mexican American Adolescents
Published on: July 10, 2017
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML Patient
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. afathi@mgh.harvard.edu.
Abstract:
A multitude of regulatory approvals has recently changed the therapeutic landscape of acute myeloid leukemia. Among these was upfront therapy with the Hedgehog inhibitor glasdegib with low-dose cytarabine. Understanding the process of and rationale for approval of this promising combination is timely and valuable for the oncology community.See related article by Norsworthy et al., p. 6021.
Related Concept Videos
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Dose-Response Relationship: Overview

